Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

WeightWatchers filed for bankruptcy on Tuesday as Americans shunned its offerings in favor of Novo and Lilly drugs and copies ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims offers a range of treatment solutions that are customized to meet your specific needs. There's no one-size-fits-all approach to weight loss, after all, and the company's offerings reflect that.

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...